ArticleFrontiers in neurology2026
Gut microbiota-derived tryptophan metabolites and inflammatory factors enhance prediction of early neurological deterioration after intravenous thrombolysis in stroke patients: a comparative model study.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Early neurological deterioration (END) after stroke thrombolysis predicts poor outcomes. This study developed predictive nomograms that incorporate gut-derived tryptophan metabolites and inflammatory markers to predict END. Methods: We evaluated demographic, clinical, and laboratory variables, including gut-derived tryptophan metabolites and inflammatory markers. A multivariable logistic regression model was developed to predict END and presented as a nomogram. Model performance was assessed using variance inflation factors, ROC analysis, calibration curves, and decision curve analysis. Net Reclassification Improvement and Integrated Discrimination Improvement were used to compare models. Results: In this study, END occurred in 11.26% of stroke patients and was independently associated with systolic blood pressure (SBP), fasting blood glucose, and serum levels of indole-3-propionic acid (IPA), indole-3-lactic acid (ILA), and interferon γ (IFN γ). Two nomogram models were developed to predict END: one based on conventional risk factors (SBP and glucose) and another incorporating emerging biomarkers (SBP, glucose, ILA, IPA, and IFN γ). The models achieved AUC scores of 0.719 (95% CI 0.658-0.780) and 0.909 (95% CI 0.879-0.939), respectively. Comparing the models showed a categorical Net Reclassification Improvement of 0.601 ( Conclusion: Incorporating gut microbiota-derived tryptophan metabolites and inflammatory factors improves prediction of END among thrombolyzed stroke patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.